Can AI remedy the growing pains of digital biomarker development?
AI implementation could be a useful tool to analyse generated data. Yet, regulatory approval hurdles are in sight.
By
AI implementation could be a useful tool to analyse generated data. Yet, regulatory approval hurdles are in sight.
ByWith the 20th birthday of the renowned Clinical Trial Supply East Coast conference in October, we look at topic changes…
ByFour Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and five…
ByMillennials and Gen Z can bring in fresh ideas but time and investment from hiring companies is required.
ByIoT devices allow sponsors to access an unprecedented volume and variety of data, but are they equipped to ride the…
ByGSK’s antisense oligonucleotide is looking to further prove its value in disrupting viral replication via a Phase III test.
ByClinical Trials Arena breaks down the two most common types of Phase 0 trials, including window of opportunity trials in…
ByDespite key advantages to Phase 0 trials in glioblastoma, sponsors have been hesitant to employ the design.
ByThank you for subscribing to Clinical Trials Arena